Palatin reports positive Phase 2 appetite suppression results

Palatin (PTN) announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered melanocortin 4 receptor – MC4R – agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide, or GLP-1/GIP, tirzepatide arm, bremelanotide alone, and tirzepatide alone arms. The study showed that patients receiving co-administered bremelanotide + tirzepatide, tirzepatide alone, and bremelanotide alone, experienced significant improvements in appetite suppression, fullness, and satiety. Patients who transitioned to placebo after initial weight loss on tirzepatide showed no improvement for appetite suppression. Overall appetite suppression: bremelanotide + tirzepatide: 71% increase; tirzepatide only: 73% increase; bremelanotide only: 71% increase. Patients who transitioned to low-dose bremelanotide after initial weight loss on tirzepatide maintained their weight without any significant regain. Topline results from the BMT-801 Phase 2 trial demonstrated statistically significant weight loss with bremelanotide co-administered with tirzepatide versus placebo over an 8-week treatment period. Palatin continues to advance its next-generation MC4R agonists targeting broad obesity indications. IND filings are anticipated by end of Q4 2025, with initial clinical data expected in the first half of 2026.